National Research Corp. (NASDAQ:NRCIA) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “National Research Corporation offers analytics and insights that facilitate revenue growth, patient, employee, customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. Its services include capture, interpretation, transmittal and benchmarking of critical data elements from various healthcare consumers. National Research Corporation is headquartered in Lincoln, Nebraska. “

Separately, TheStreet raised National Research Corp. from a “hold” rating to a “buy” rating in a research report on Wednesday, August 10th.

National Research Corp. (NASDAQ:NRCIA) opened at 15.55 on Wednesday. The firm’s 50-day moving average price is $16.06 and its 200 day moving average price is $14.92. National Research Corp. has a 52 week low of $12.02 and a 52 week high of $17.42. The firm has a market cap of $376.64 million, a P/E ratio of 19.10 and a beta of 1.69.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Friday, September 30th will be given a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 2.06%. The ex-dividend date is Wednesday, September 28th. National Research Corp.’s dividend payout ratio is presently 68.09%.

5 Day Chart for NASDAQ:NRCIA

Receive News & Stock Ratings for National Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corp. and related stocks with our FREE daily email newsletter.